Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samuel D Vasikaran

Showing results (11-20 of 69) with videos related to

Pageof 7
Sort By:
Pathology|July 12, 2002
Surgically correctable hypertensionPaul Glendenning, Samuel D Vasikaran
The Clinical Biochemist. Reviews|January 16, 2018
Clinical Utility and Measurement of ProcalcitoninIntan Samsudin, Samuel D Vasikaran
Annals of Clinical Biochemistry|June 1, 2002
Cardiovascular disease and osteoporosis: is there a link between lipids and bone?John R Burnett, Samuel D Vasikaran
Pathology|February 18, 2006
Urinary NTX results rarely alter the clinical management of patients with osteoporosis in the tertiary hospitalMelissa J Gillett, Samuel D Vasikaran
Annals of Clinical Biochemistry|October 8, 2010
An audit of management of patients with borderline increased plasma-free metanephrinesSiti Sharina Anas, Samuel D Vasikaran
Advances in Clinical Chemistry|June 21, 2017
Measurement and Clinical Utility of βCTX in Serum and PlasmaStephen A P Chubb, Samuel D Vasikaran
Annals of Clinical Biochemistry|June 1, 2002
Decision limit for troponin I and assay performancePaul Sheehan, John Blennerhassett, Samuel D Vasikaran
Pathology|January 21, 2026
Proposed common reference intervals for reference bone turnover markers in osteoporosisS A Paul Chubb, Samuel D Vasikaran
Annals of Clinical Biochemistry|July 31, 2009
An audit of oral glucose tolerance tests at a large teaching hospital: indications, outcomes and confounding factorsJoshua Ryan, Deepani Siriwardhana, Samuel D Vasikaran
Endocrine|February 25, 2016
The use of biochemical markers of bone turnover in the clinical management of primary and secondary osteoporosisSamuel D Vasikaran, S A Paul Chubb
Pageof 7

Showing results (11-20 of 69) with videos related to

Sort By:
Pageof 7
Pathology|July 12, 2002
Surgically correctable hypertensionPaul Glendenning, Samuel D Vasikaran
The Clinical Biochemist. Reviews|January 16, 2018
Clinical Utility and Measurement of ProcalcitoninIntan Samsudin, Samuel D Vasikaran
Annals of Clinical Biochemistry|June 1, 2002
Cardiovascular disease and osteoporosis: is there a link between lipids and bone?John R Burnett, Samuel D Vasikaran
Pathology|February 18, 2006
Urinary NTX results rarely alter the clinical management of patients with osteoporosis in the tertiary hospitalMelissa J Gillett, Samuel D Vasikaran
Annals of Clinical Biochemistry|October 8, 2010
An audit of management of patients with borderline increased plasma-free metanephrinesSiti Sharina Anas, Samuel D Vasikaran
Advances in Clinical Chemistry|June 21, 2017
Measurement and Clinical Utility of βCTX in Serum and PlasmaStephen A P Chubb, Samuel D Vasikaran
Annals of Clinical Biochemistry|June 1, 2002
Decision limit for troponin I and assay performancePaul Sheehan, John Blennerhassett, Samuel D Vasikaran
Pathology|January 21, 2026
Proposed common reference intervals for reference bone turnover markers in osteoporosisS A Paul Chubb, Samuel D Vasikaran
Annals of Clinical Biochemistry|July 31, 2009
An audit of oral glucose tolerance tests at a large teaching hospital: indications, outcomes and confounding factorsJoshua Ryan, Deepani Siriwardhana, Samuel D Vasikaran
Endocrine|February 25, 2016
The use of biochemical markers of bone turnover in the clinical management of primary and secondary osteoporosisSamuel D Vasikaran, S A Paul Chubb
Pageof 7